Comparison of the CytoSorb® 300 mL and Jafron HA380 hemoadsorption devices: an in vitro study
We performed an analysis of two blood purification systems to determine their performance for removing interleukins (ILs)-6 and 10, tumor necrosis factor (TNF)-α and monocyte chemoattractant protein (MCP)-1 from blood. An in vitro hemoperfusion blood recirculation circuit was used to compare the Cyt...
Saved in:
| Published in | Minimally Invasive Therapy & Allied Technologies Vol. 31; no. 7; pp. 1058 - 1065 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English Japanese |
| Published |
Taylor & Francis
03.10.2022
Informa UK Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | We performed an analysis of two blood purification systems to determine their performance for removing interleukins (ILs)-6 and 10, tumor necrosis factor (TNF)-α and monocyte chemoattractant protein (MCP)-1 from blood.
An in vitro hemoperfusion blood recirculation circuit was used to compare the CytoSorb
®
300 mL (CytoSorbents Inc., Princeton, NJ) and Jafron HA 380 (Jafron Biomedical Co., Ltd., Zhuhai City, China) devices. The removal of purified recombinant human IL-6, IL-10, TNFα and MCP-1 by the adsorbers was compared at various timepoints. Three runs were completed and removal was evaluated as the mean area under the curve (AUC).
Both devices showed effective removal of the tested cytokines. IL-6, IL-10, TNFα and MCP-1 were removed faster and to a higher extent by the CytoSorb
®
300 mL device. At maximal time of 12 h, overall removal according to AUC of remaining concentrations was significantly lower with CytoSorb
®
300 mL compared with HA 380 (IL-6: 1075.5 ± 665.9 vs. 4345.1 ± 1499.3 (p = 0.01), IL-10: 5065.7 ± 882.5 vs. 11,939.7 ± 4523.1 (p = 0.03), TNF-α: 6519.9 ± 997.6 vs. 10,303.7 ± 2347.0 (p = 0.03) and MCP-1: 278.9 ± 40.7 vs. 607.3 ± 84.4 (p = 0.001)).
Both the CytoSorb
®
and the Jafron HA 380 devices are capable of removing cytokines from blood in a benchtop model. The CytoSorb
®
300 device was significantly more efficient achieving the bulk of the removal in the first 120 min. |
|---|---|
| AbstractList | We performed an analysis of two blood purification systems to determine their performance for removing interleukins (ILs)-6 and 10, tumor necrosis factor (TNF)-α and monocyte chemoattractant protein (MCP)-1 from blood.
An in vitro hemoperfusion blood recirculation circuit was used to compare the CytoSorb
®
300 mL (CytoSorbents Inc., Princeton, NJ) and Jafron HA 380 (Jafron Biomedical Co., Ltd., Zhuhai City, China) devices. The removal of purified recombinant human IL-6, IL-10, TNFα and MCP-1 by the adsorbers was compared at various timepoints. Three runs were completed and removal was evaluated as the mean area under the curve (AUC).
Both devices showed effective removal of the tested cytokines. IL-6, IL-10, TNFα and MCP-1 were removed faster and to a higher extent by the CytoSorb
®
300 mL device. At maximal time of 12 h, overall removal according to AUC of remaining concentrations was significantly lower with CytoSorb
®
300 mL compared with HA 380 (IL-6: 1075.5 ± 665.9 vs. 4345.1 ± 1499.3 (p = 0.01), IL-10: 5065.7 ± 882.5 vs. 11,939.7 ± 4523.1 (p = 0.03), TNF-α: 6519.9 ± 997.6 vs. 10,303.7 ± 2347.0 (p = 0.03) and MCP-1: 278.9 ± 40.7 vs. 607.3 ± 84.4 (p = 0.001)).
Both the CytoSorb
®
and the Jafron HA 380 devices are capable of removing cytokines from blood in a benchtop model. The CytoSorb
®
300 device was significantly more efficient achieving the bulk of the removal in the first 120 min. We performed an analysis of two blood purification systems to determine their performance for removing interleukins (ILs)-6 and 10, tumor necrosis factor (TNF)-α and monocyte chemoattractant protein (MCP)-1 from blood.INTRODUCTIONWe performed an analysis of two blood purification systems to determine their performance for removing interleukins (ILs)-6 and 10, tumor necrosis factor (TNF)-α and monocyte chemoattractant protein (MCP)-1 from blood.An in vitro hemoperfusion blood recirculation circuit was used to compare the CytoSorb® 300 mL (CytoSorbents Inc., Princeton, NJ) and Jafron HA 380 (Jafron Biomedical Co., Ltd., Zhuhai City, China) devices. The removal of purified recombinant human IL-6, IL-10, TNFα and MCP-1 by the adsorbers was compared at various timepoints. Three runs were completed and removal was evaluated as the mean area under the curve (AUC).MATERIAL AND METHODSAn in vitro hemoperfusion blood recirculation circuit was used to compare the CytoSorb® 300 mL (CytoSorbents Inc., Princeton, NJ) and Jafron HA 380 (Jafron Biomedical Co., Ltd., Zhuhai City, China) devices. The removal of purified recombinant human IL-6, IL-10, TNFα and MCP-1 by the adsorbers was compared at various timepoints. Three runs were completed and removal was evaluated as the mean area under the curve (AUC).Both devices showed effective removal of the tested cytokines. IL-6, IL-10, TNFα and MCP-1 were removed faster and to a higher extent by the CytoSorb® 300 mL device. At maximal time of 12 h, overall removal according to AUC of remaining concentrations was significantly lower with CytoSorb® 300 mL compared with HA 380 (IL-6: 1075.5 ± 665.9 vs. 4345.1 ± 1499.3 (p = 0.01), IL-10: 5065.7 ± 882.5 vs. 11,939.7 ± 4523.1 (p = 0.03), TNF-α: 6519.9 ± 997.6 vs. 10,303.7 ± 2347.0 (p = 0.03) and MCP-1: 278.9 ± 40.7 vs. 607.3 ± 84.4 (p = 0.001)).RESULTSBoth devices showed effective removal of the tested cytokines. IL-6, IL-10, TNFα and MCP-1 were removed faster and to a higher extent by the CytoSorb® 300 mL device. At maximal time of 12 h, overall removal according to AUC of remaining concentrations was significantly lower with CytoSorb® 300 mL compared with HA 380 (IL-6: 1075.5 ± 665.9 vs. 4345.1 ± 1499.3 (p = 0.01), IL-10: 5065.7 ± 882.5 vs. 11,939.7 ± 4523.1 (p = 0.03), TNF-α: 6519.9 ± 997.6 vs. 10,303.7 ± 2347.0 (p = 0.03) and MCP-1: 278.9 ± 40.7 vs. 607.3 ± 84.4 (p = 0.001)).Both the CytoSorb® and the Jafron HA 380 devices are capable of removing cytokines from blood in a benchtop model. The CytoSorb® 300 device was significantly more efficient achieving the bulk of the removal in the first 120 min.CONCLUSIONSBoth the CytoSorb® and the Jafron HA 380 devices are capable of removing cytokines from blood in a benchtop model. The CytoSorb® 300 device was significantly more efficient achieving the bulk of the removal in the first 120 min. |
| Author | Wendt, Daniel Born, Frank Nierhaus, Axel Hagl, Christian Deliargyris, Efthymios Morales, Jesus Scheier, Jörg Jarczak, Dominik Mehta, Yatin Gutzler, Dominik |
| Author_xml | – sequence: 1 givenname: Axel orcidid: 0000-0001-5493-7964 surname: Nierhaus fullname: Nierhaus, Axel organization: Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf – sequence: 2 givenname: Jesus surname: Morales fullname: Morales, Jesus organization: CytoSorbents – sequence: 3 givenname: Daniel surname: Wendt fullname: Wendt, Daniel organization: Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center Essen – sequence: 4 givenname: Jörg surname: Scheier fullname: Scheier, Jörg organization: CytoSorbents – sequence: 5 givenname: Dominik surname: Gutzler fullname: Gutzler, Dominik organization: CytoSorbents – sequence: 6 givenname: Dominik orcidid: 0000-0003-0480-2089 surname: Jarczak fullname: Jarczak, Dominik organization: Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf – sequence: 7 givenname: Frank surname: Born fullname: Born, Frank organization: Department of Cardiac Surgery, University Hospital, LMU Munich – sequence: 8 givenname: Christian surname: Hagl fullname: Hagl, Christian organization: Department of Cardiac Surgery, University Hospital, LMU Munich – sequence: 9 givenname: Efthymios surname: Deliargyris fullname: Deliargyris, Efthymios organization: CytoSorbents – sequence: 10 givenname: Yatin surname: Mehta fullname: Mehta, Yatin organization: Medanta Institute of Critical Care and Anesthesiology |
| BackLink | https://cir.nii.ac.jp/crid/1871428067734852608$$DView record in CiNii |
| BookMark | eNqFkDFuFDEUhi0UJJLAEZBcUNDM8mzPeDzQEK2AgFaiAGrrre1RjGbsxfYm2o6WW3ACDpGjcBI8bGgooPGzfn3_s_ydkZMQgyPkMYMVAwXPmJBt14NcceB8xRm0kvX3yGnNu4YPgp38vrfNAj0gZzl_BuCsE-qU4DrOO0w-x0DjSMuVo-tDiR9i2t7-oALg59dv84ZisPQdjqlSlxdCAb1yc0SbY9oVX0Prrr1x-XkFqQ-33699SZHmsreHh-T-iFN2j-7mOfn0-tXH9WWzef_m7fpi05hWqNIM1oJw4CTD1hoE3pledlKiwUFgp7aj3bJWOcYtuJqglaz-viYCGEMjzsnT495dil_2Lhc9-2zcNGFwcZ81l0MPAwcJFe2OqEkx5-RGvUt-xnTQDPSiVP9Rqhel-k5p7b34q2d8wUVASein_7afHNvB-1pcTqZ61nIFsu9FqzouQVXs5RHzYYxpxpuYJqsLHqaYxoTB-KzFv1_6BSlnnIw |
| CitedBy_id | crossref_primary_10_1186_s13054_023_04517_3 crossref_primary_10_1016_j_xjon_2023_04_013 crossref_primary_10_1093_icvts_ivad010 crossref_primary_10_3390_jcdd10040146 crossref_primary_10_1186_s12872_024_03938_4 crossref_primary_10_1186_s40635_025_00740_0 crossref_primary_10_1007_s11560_024_00795_2 crossref_primary_10_1159_000542469 crossref_primary_10_1016_j_carrev_2025_02_015 crossref_primary_10_1186_s13019_024_03326_1 crossref_primary_10_1186_s13054_024_05220_7 crossref_primary_10_5492_wjccm_v12_i2_71 crossref_primary_10_3390_jcm12020546 crossref_primary_10_1093_icvts_ivae050 crossref_primary_10_3390_jcm13247694 crossref_primary_10_1177_02676591241305276 crossref_primary_10_1186_s13019_024_02772_1 crossref_primary_10_3390_jcm11237005 crossref_primary_10_3389_fcvm_2025_1512619 crossref_primary_10_3390_jcm11195889 crossref_primary_10_1007_s11239_024_02996_x crossref_primary_10_1186_s13054_023_04310_2 |
| Cites_doi | 10.1097/CCE.0000000000000688 10.1177/0885066610384465 10.1186/s13613-021-00905-6 10.1001/jama.2016.0287 10.1097/CCM.0000000000005023 10.1016/S0140-6736(19)32989-7 10.1177/03913988211073812 10.1053/j.jvca.2020.06.028 10.1186/s13054-021-03813-0 10.3389/fmed.2021.773461 10.1016/j.athoracsur.2019.12.067 10.1371/journal.pone.0191676 10.1159/000512309 10.1093/ehjcvp/pvac036 10.3390/jcm11113106 10.1097/CCM.0000000000000330 10.1159/000468911 10.1007/s10047-017-0967-4 |
| ContentType | Journal Article |
| Copyright | 2022 Society of Medical Innovation and Technology 2022 |
| Copyright_xml | – notice: 2022 Society of Medical Innovation and Technology 2022 |
| DBID | RYH AAYXX CITATION 7X8 |
| DOI | 10.1080/13645706.2022.2104617 |
| DatabaseName | CiNii Complete CrossRef MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-2931 |
| EndPage | 1065 |
| ExternalDocumentID | 10_1080_13645706_2022_2104617 2104617 |
| Genre | Research Article |
| GroupedDBID | --- 00X 03L 04C 0BK 0R~ 123 29M 36B 4.4 6PF AALUX AAMIU AAPUL AAQRR AAWTL ABBKH ABDBF ABEIZ ABJNI ABLIJ ABLKL ABUPF ABXYU ACENM ACGEJ ACGFS ACIEZ ACUHS ADBBV ADCVX ADOJX ADRBQ ADXPE AECIN AENEX AEOZL AFKVX AGDLA AGFJD AGRBW AGYJP AIJEM AIRBT AJWEG AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU ALYBC AMDAE BABNJ BLEHA BMSDO BOHLJ CCCUG CS3 DKSSO DU5 EAP EBC EBD EBS ECT EIHBH EMB EMK EMOBN EPL ESX F5P H13 HZ~ KRBQP KSSTO KWAYT KYCEM LJTGL M4Z O9- RNANH RVRKI SV3 TBQAZ TDBHL TERGH TFDNU TFL TFW TUROJ TUS UEQFS V1S ~1N AAGDL ABWVI ADYSH AFRVT AMPGV RYH AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c438t-9dd03e0e61a4dca025c76566aca93a58bfdb148e12d0e93aad6110848e3011ac3 |
| ISSN | 1364-5706 1365-2931 |
| IngestDate | Fri Jul 11 04:49:53 EDT 2025 Tue Jul 01 04:37:37 EDT 2025 Thu Apr 24 22:52:51 EDT 2025 Thu Jun 26 23:58:26 EDT 2025 Wed Dec 25 09:05:50 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c438t-9dd03e0e61a4dca025c76566aca93a58bfdb148e12d0e93aad6110848e3011ac3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-5493-7964 0000-0003-0480-2089 |
| PQID | 2697092060 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | nii_cinii_1871428067734852608 proquest_miscellaneous_2697092060 crossref_citationtrail_10_1080_13645706_2022_2104617 informaworld_taylorfrancis_310_1080_13645706_2022_2104617 crossref_primary_10_1080_13645706_2022_2104617 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-10-03 |
| PublicationDateYYYYMMDD | 2022-10-03 |
| PublicationDate_xml | – month: 10 year: 2022 text: 2022-10-03 day: 03 |
| PublicationDecade | 2020 |
| PublicationTitle | Minimally Invasive Therapy & Allied Technologies |
| PublicationYear | 2022 |
| Publisher | Taylor & Francis Informa UK Limited |
| Publisher_xml | – name: Taylor & Francis – name: Informa UK Limited |
| References | e_1_3_2_9_1 e_1_3_2_17_1 e_1_3_2_8_1 e_1_3_2_18_1 e_1_3_2_7_1 Goetz G (e_1_3_2_16_1) 2021; 49 e_1_3_2_19_1 e_1_3_2_2_1 e_1_3_2_20_1 e_1_3_2_10_1 e_1_3_2_11_1 e_1_3_2_6_1 e_1_3_2_12_1 e_1_3_2_5_1 e_1_3_2_13_1 e_1_3_2_4_1 e_1_3_2_14_1 e_1_3_2_3_1 e_1_3_2_15_1 |
| References_xml | – ident: e_1_3_2_19_1 doi: 10.1097/CCE.0000000000000688 – ident: e_1_3_2_3_1 doi: 10.1177/0885066610384465 – ident: e_1_3_2_15_1 doi: 10.1186/s13613-021-00905-6 – ident: e_1_3_2_5_1 doi: 10.1001/jama.2016.0287 – volume: 49 start-page: 1347 issue: 8 year: 2021 ident: e_1_3_2_16_1 article-title: Extracorporeal cytokine adsorption therapy as a preventive measure in cardiac surgery and as a therapeutic add-on treatment in sepsis: an updated systematic review of comparative efficacy and safety publication-title: Crit Care Med doi: 10.1097/CCM.0000000000005023 – ident: e_1_3_2_2_1 doi: 10.1016/S0140-6736(19)32989-7 – ident: e_1_3_2_18_1 doi: 10.1177/03913988211073812 – ident: e_1_3_2_11_1 doi: 10.1053/j.jvca.2020.06.028 – ident: e_1_3_2_6_1 doi: 10.1186/s13054-021-03813-0 – ident: e_1_3_2_13_1 – ident: e_1_3_2_12_1 doi: 10.3389/fmed.2021.773461 – ident: e_1_3_2_10_1 doi: 10.1016/j.athoracsur.2019.12.067 – ident: e_1_3_2_7_1 doi: 10.1371/journal.pone.0191676 – ident: e_1_3_2_4_1 doi: 10.1159/000512309 – ident: e_1_3_2_20_1 doi: 10.1093/ehjcvp/pvac036 – ident: e_1_3_2_14_1 doi: 10.3390/jcm11113106 – ident: e_1_3_2_17_1 doi: 10.1097/CCM.0000000000000330 – ident: e_1_3_2_8_1 doi: 10.1159/000468911 – ident: e_1_3_2_9_1 doi: 10.1007/s10047-017-0967-4 |
| SSID | ssj0021538 ssib004908975 ssib020359410 ssib020737759 ssib018143077 |
| Score | 2.4191575 |
| Snippet | We performed an analysis of two blood purification systems to determine their performance for removing interleukins (ILs)-6 and 10, tumor necrosis factor... |
| SourceID | proquest crossref nii informaworld |
| SourceType | Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 1058 |
| SubjectTerms | blood purification cytokines Hemoadsorption Medizin porous polymer beads sepsis |
| Title | Comparison of the CytoSorb® 300 mL and Jafron HA380 hemoadsorption devices: an in vitro study |
| URI | https://www.tandfonline.com/doi/abs/10.1080/13645706.2022.2104617 https://cir.nii.ac.jp/crid/1871428067734852608 https://www.proquest.com/docview/2697092060 |
| Volume | 31 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NjxIxGG6QTYwX42dk1zU10ZMZLNP56HgDhBCCeBAit7HT6WQngRkDw2b15NWLP8Uf4U_xl_h22oEhkuzqZYBOC5O-D-3z9v1C6IVgTLiuH1kscUFBkUlgAZQDi1KXCZt6nMrSQXbqjebOeOEuGo0fNa-lbRG1xdejcSX_I1VoA7mqKNl_kOzuS6EB3oN84QoShuuNZNyvFxEsKWT_S5F_yNfAEe2X3cErVYNZezOwYDUpDQVjnqyh_6hLGQGauMp5vMnXeuGIpV43VAB06QF5mRbrvJaCtir9lGbpii-XKmbwkpcO8DqOSydzgjuK2BbVqX3NT3EKu_AF3-oSyFdy75SoEgVIE1u22e76f5RZXOxD4fdmowuZarCNlam_55k8Xeb8AlRfZX2ntSW39LMLzF4gj7SZddp80nj0a4suUER2dDfQ7pMdZWn1ifJHse22rYzaOlz0MPv29H04nE8m4WywmN1CJzaoHXYTnXR7b3vDnQqv9oddJB88XxUTxsjroz9zwHYOcuECl8nS9C8GUNKa2T101-gjuKvBdR81ZPYA3X5nPC4eok97jOE8wSBmXGHs108M-Pr97ftqgkHsWCMLl8jCh8jCBllvoCNOM1ziCpe4eoTmw8GsP7JMVQ5LOJQVVhDHhEoivQ53YsGBMwtfKQVc8IByl0VJHIGOLTt2TCS08NhToSbQovYSLuhj1MzyTD5BOEqcRBH2wJOBo14TIohwBUsE3GFuCznV7IXCpKxXlVOWYcdktq0mPVSTHppJb6H2bthnnbPlugFBXTRhUR6WJbqyTUivGXsOcoTHU9cO81UGQ5WVkTrMtT3CWuh5JeEQVm5ljuOZzLeb0PYCnwQ28cjpDfqcoTv7f89T1CzWW3kOfLiInhmQ_gHdcqoc |
| linkProvider | EBSCOhost |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+the+CytoSorb%C2%AE+300%E2%80%89mL+and+Jafron+HA380+hemoadsorption+devices%3A+an+in+vitro+study&rft.jtitle=Minimally+invasive+therapy+and+allied+technologies&rft.au=Nierhaus%2C+Axel&rft.au=Morales%2C+Jesus&rft.au=Wendt%2C+Daniel&rft.au=Scheier%2C+J%C3%B6rg&rft.date=2022-10-03&rft.issn=1365-2931&rft.eissn=1365-2931&rft.volume=31&rft.issue=7&rft.spage=1058&rft_id=info:doi/10.1080%2F13645706.2022.2104617&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1364-5706&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1364-5706&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1364-5706&client=summon |